Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 9/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 5/20 | 0.34 |
| ▸ | IDO1 | P14902 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442864 | 0.80 | ROCK1 (0.42) | AKT1F10SCN9AIDO1GSK3B | |
| SCHEMBL12044601 | 0.78 | RAB9A (0.41) | AKT1SCN9A | |
| SCHEMBL28372349 | 0.78 | AKT1 (0.36) | AKT1F10SCN9AF2IDO1 | |
| Hydrochloric Acid SCHEMBL17442621 | 0.78 | ROCK1 (0.41) | AKT1F10SCN9AIDO1GSK3B | |
| SCHEMBL8358457 | 0.75 | NPC1 (0.45) | IDO1GSK3B | |
| SCHEMBL2634187 | 0.75 | EPHX2 (0.58) | AKT1F10EPHX2F2 | |
| SCHEMBL30410154 | 0.75 | EPHX2 (0.58) | AKT1F10EPHX2F2 | |
| SCHEMBL13486441 | 0.74 | IKBKE (0.45) | AKT1SCN9AGSK3BNTRK1 | |
| SCHEMBL3547238 | 0.73 | MAPT (0.49) | F10SCN9ANTRK1 | |
| SCHEMBL2441701 | 0.72 | HTR3A (0.40) | SCN9AIDO1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436023-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | AKT1 3431/4885F10 2193/4885EPHX2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.